Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.7% – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price was down 6.7% during mid-day trading on Wednesday . The stock traded as low as $21.72 and last traded at $21.9420. 1,059,456 shares changed hands during mid-day trading, a decline of 22% from the average daily volume of 1,364,818 shares. The stock had previously closed at $23.52.

Wall Street Analysts Forecast Growth

CAPR has been the topic of a number of recent research reports. Piper Sandler reiterated an “overweight” rating and set a $45.00 price target (up from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. Maxim Group lifted their price target on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 29th. Oppenheimer raised their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Capricor Therapeutics in a research note on Wednesday, January 14th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $40.82.

Capricor Therapeutics Stock Performance

The stock has a market cap of $986.18 million, a P/E ratio of -11.98 and a beta of 0.22. The firm has a 50-day moving average price of $22.32 and a 200-day moving average price of $12.26.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.54). On average, research analysts predict that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. GoalVest Advisory LLC bought a new position in Capricor Therapeutics in the 4th quarter worth about $59,000. PVG Asset Management Corp purchased a new position in shares of Capricor Therapeutics during the third quarter valued at approximately $91,000. Voleon Capital Management LP purchased a new stake in Capricor Therapeutics in the third quarter worth approximately $311,000. Moneta Group Investment Advisors LLC raised its stake in Capricor Therapeutics by 25.5% during the 3rd quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 7,000 shares during the last quarter. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth $123,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.